Senores Pharmaceuticals Ltd. News and Updates

Name: Latest research reports of Senores Pharmaceuticals Ltd. authored by SBI Securities and published by - Trendlyne research reports.
Item: Senores Pharmaceuticals Ltd.
Rating: 5
Author: SBI Securities

Keep track of all breaking news on Senores Pharmaceuticals Ltd. from all sources in a single place.

Load latest

Senores Pharmaceuticals Ltd.

20 Dec 2024

570.60

-2.86%

Senores Pharma has niche positives, can be a long-term bet

Economic Times

Incorporated in 2017, the company identifies, develops and commercialises speciality and complex niche products in mid-market range. It also undertakes contract manufacturing for its customers. It earns through in-licensing fee, transfer pricing and profit sharing. Over 60% of its revenues come from supplying to regulated markets of the US, Canada and the UK and 32% from emerging markets.

Senores Pharmaceuticals Ltd. has gained 45.93% in the last 6 Months

Senores Pharmaceuticals IPO: From price band, GMP, to lot size: 10 key things to know as issue opens …

livemint | 19 Dec 2024

Senores Pharmaceuticals Ltd.

19 Dec 2024

570.60

-2.86%

Senores Pharmaceuticals Ltd IPO Note

IPO Subscribe: Senores Pharmaceuticals Ltd.

SBI Securities

Senores Pharmaceuticals Ltd. has gained 45.93% in the last 1 Year

Senores Pharmaceuticals Ltd.

19 Dec 2024

570.60

-2.86%

IPO Note

IPO Note: Senores Pharmaceuticals Ltd.

KRChoksey

Senores Pharmaceuticals focuses on generic drugs and specialty medications across various therapeutic areas, including cardiovascular, diabetes, gastroenterology, and critical care injectables. The company manufactures products at its FDA-approved facilities, with a significant presence in regulated markets like the US, UK, and Canada.

31.10% Gain from 52W Low

Senores Pharmaceuticals Ltd. News and Updates

Keep track of all breaking news on Senores Pharmaceuticals Ltd. from all sources in a single place.